Procell Biologics Profile
Key Indicators
- Authorised Capital ₹ 11.00 Cr
as on 12-12-2024
- Paid Up Capital ₹ 10.37 Cr
as on 12-12-2024
- Company Age 3 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.00 M
as on 12-12-2024
- Revenue %
(FY 2023)
- Profit -114.98%
(FY 2023)
- Ebitda -123.83%
(FY 2023)
- Net Worth 141.31%
(FY 2023)
- Total Assets 13.89%
(FY 2023)
About Procell Biologics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 11.00 Cr and a paid-up capital of Rs 10.37 Cr.
The company currently has active open charges totaling ₹3.00 M.
The Key Managerial Personnel (KMP) at Procell Biologics Private Limited India is Megha Aggarwal as COMPANY SECRETARY. Muni Akkina, Venkata Cherukuri, Surya Akkina, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24290TG2021PTC150610
- Company No.
150610
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Apr 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Procell Biologics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Megha Aggarwal | Company Secretary | 29-Mar-2024 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Muni Akkina  | Director | 14-Apr-2021 | Current |
| Venkata Cherukuri | Director | 14-Apr-2021 | Current |
| Surya Akkina | Director | 14-Apr-2021 | Current |
| Srinivasa Akkina | Director | 14-Apr-2021 | Current |
| Srinivas Cherukuri | Director | 14-Apr-2021 | Current |
Financial Performance and Corporate Structure Insights of Procell Biologics.
Procell Biologics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 114.98% decrease in profit. The company's net worth Soared by an impressive increase of 141.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Procell Biologics?
In 2023, Procell Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Veeraaya Techno Plast Private LimitedActive 15 years 7 monthsVenkata Cherukuri and Srinivasa Akkina are mutual person
Lextro Bio Solutions Private LimitedActive 2 years 5 monthsMuni Akkina, Venkata Cherukuri and 2 more are mutual person
- Ch.Veerraju Mines & Minerals Private LimitedActive 18 years 7 months
Muni Akkina, Venkata Cherukuri and 1 more are mutual person
- Cherukuri Veerraju Industries Private LimitedActive 18 years 7 months
Muni Akkina, Venkata Cherukuri and 2 more are mutual person
- Lextro Labs Private LimitedActive 2 years 6 months
Muni Akkina, Venkata Cherukuri and 2 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Oct 2023 | ₹3.00 M | Open |
How Many Employees Work at Procell Biologics?
Procell Biologics has a workforce of 39 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Procell Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Procell Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
